Designer α 6-fucosidase mutants enable direct core fucosylation of intact N-glycopeptides and N-glycoproteins
The present invention provides for novel fucosidase mutants that server as fuco-ligases for core fucosylation of a range of biological glycopeptides and glycoproteins including intact therapeutic antibodies. Several mutants with mutation at the general acid/base residue E274 of the Lactobacillus casei α1,6-fucosidase, including E274A, E274S, and E274G, were able to efficiently fucosylate a wide variety of complex N-glycopeptides and intact glycoproteins. The site specific mutants enable the transfer of fucose to a core GlcNAc-Asn residue and useful for drug delivery and vaccine development.
1. A mutated α1-6-fucosidase enzyme selected from the group consisting of E274A (SEQ ID NO: 1), E274S (SEQ ID NO: 2), and E274G (SEQ ID NO: 3).
2. A kit comprising a least one Lactobacillus casei α-fucosidase mutant selected from the group consisting of E274A (SEQ ID NO: 1), E274S (SEQ ID NO: 2), and E274G (SEQ ID NO: 3).
3. A catalytic method for fucosylating a N-glycopeptide or N-glycoprotein, the method comprising:
providing a GlcNAc acceptor substrate comprising a GlcNAc containing peptide or protein, or an oligosaccharide containing a terminal GlcNAc moiety;
providing an activated glycosyl donor for access to a sugar fucose; and
providing an α1,6-fucosidase mutant enzyme for enzymatically transfucosylating the GlcNAc acceptor substrate with the sugar fucose,
wherein the α1,6-fucosidase mutant enzyme is a Lactobacillus casei α1,6-fucosidase mutant, thereby synthesizing a fucosylated glycopeptide or glycoprotein, wherein α1,6-fucosidase mutant enzyme is selected from a group consisting of E274A (SEQ ID NO: 1), E274S (SEQ ID NO: 2), and E274G (SEQ ID NO:3) derived from Lactobacillus casei α-fucosidase (SEQ ID NO: 4).
4. The catalytic method according to claim 3 , wherein the activated glycosyl donor is selected from the group consisting of α-fucosyl fluoride αFucF, α-fucosyl chloride, α-fucosyl azide, 4-nitrophenyl α-fucoside, 3-nitrophenyl α-fucoside, 3,4-dinitrophenyl α-fucoside, and 4-methylumbelliferyl α-fucoside.
5. The catalytic method according to claim 3 , further comprising a cysteine protease domain (CPD) and poly histidine (HIS) (SEQ ID NO: 31) or a CPD (SEQ ID NO: 30) polypeptide.
6. A chemoenzymatic method for the preparation of homogeneous fucosylated glycopeptides or glycoproteins, comprising:
providing a nonfucosylated glycopeptide or glycoprotein acceptor; and
reacting the nonfucosylated glycopeptide or glycoprotein acceptor with a donor substrate including an activated fucose containing moiety, in the presence of a Lactobacillus casei al-6-fucosidase E274 mutant protein or fragment thereof comprising a catalytic domain having a E274 mutation and exhibits increased transfucosylation and reduced hydrolytic activity relative to the wild type α1-6-fucosidase E274 enzyme (SEQ ID NO: 4) to transfer the activated fucose containing moiety to the nonfucosylated glycopeptide or glycoprotein acceptor and yielding the homogeneous fucosylated glycopeptides or glycoproteins, wherein α1,6-fucosidase mutant enzyme is selected from a group consisting of E274A (SEQ ID NO: 1), E274S (SEQ ID NO: 2), and E274G (SEQ ID NO:3).
7. The chemoenzymatic method according to claim 6 , wherein the homogeneous fucosylated glycopeptides and glycoproteins include glycans attached to the glycopeptides or glycoproteins selected from high mannose type, sialylated and asialo-complex type, hybrid type and their analogs.
8. The chemoenzymatic method according to claim 6 , wherein the nonfucosylated glycopeptide or glycoprotein acceptor include one or more Asn(asparagine)-linked GlcNAc moieties or one or more N-glycan sites to allow introduction of one or multiple core fucoses.
9. The chemoenzymatic method according to claim 6 , wherein the fucosylated glycopeptides or glycoproteins is an antibody, wherein the antibody is selected from a group consisting of 17b, 48d, A32, C11, 2G12, F240, IgG1b12, 19e, X5, TNX-355, cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, I131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, MDX-010, MDX-060, MDX-070, matuzumab, CP-675,206, CAL, SGN-30, zanolimumab, adecatumumab, oregovomab, nimotuzumab, ABT-874, denosumab, AM 108, AMG 714, fontolizumab, daclizumab, golimumab, CNTO 1275, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, MLN1202, visilizumab, tocilizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranbizumab, mepolizumab and MYO-029.
10. The chemoenzymatic method according to claim 6 , wherein the activated fucose containing moiety is selected from the group consisting of α-fucosyl fluoride αFucF, α-fucosyl chloride, α-fucosyl azide, 4-nitrophenyl α-fucoside, 3-nitrophenyl α-fucoside, 3,4-dinitrophenyl α-fucoside, and 4-methylumbelliferyl α-fucoside.
11. The chemoenzymatic method according to claim 6 , further comprising a cysteine protease domain (CPD) and HIS (SEQ ID NO: 31) or a CPD (SEQ ID NO: 30) polypeptide.